High CD56++CD16- natural killer (NK) cells among suboptimal immune responders after four years of suppressive antiretroviral therapy in an African adult HIV treatment cohort

[1] Gazzola L(2009)The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options Clin Infect Dis 48 328-337

[2] Tincati C(2005)Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy Clin Infect Dis 41 361-372

[3] Bellistri GM(2008)Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on antiretroviral therapy (ART) in sub-Saharan Africa: frequency and clinical significance AIDS Res Ther 5 23-67

[4] Monforte A(2011)High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort BMC Infect Dis 11 43-6045

[5] Marchetti G(2013)Immune activation while on potent antiretroviral therapy can predict subsequent CD4+ T-Cell increases through 15 years of treatment HIV Clin Trials 14 61-744

[6] Kaufmann GR(2003)NK cells respond to pulmonary infection with Mycobacterium tuberculosis, but play a minimal role in protection J Immunol 171 6039-510

[7] Furrer H(2006)[NK cells and innate immunity to malaria] Med Sci (Paris) 22 739-3370

[8] Ledergerber B(2008)Functions of natural killer cells Nat Immunol 9 503-843

[9] Perrin L(2007)Natural killer cells in perinatally HIV-1-infected children exhibit less degranulation compared to HIV-1-exposed uninfected children and their expression of KIR2DL3, NKG2C, and NKp46 correlates with disease severity J Immunol 179 3362-15016

[10] Opravil M(2005)NK cells in HIV infection: paradigm for protection or targets for ambush Nat Rev Immunol 5 835-318

[1] Gazzola L(2009)The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options Clin Infect Dis 48 328-337

[2] Tincati C(2005)Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy Clin Infect Dis 41 361-372

[3] Bellistri GM(2008)Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on antiretroviral therapy (ART) in sub-Saharan Africa: frequency and clinical significance AIDS Res Ther 5 23-67

[4] Monforte A(2011)High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort BMC Infect Dis 11 43-6045

[5] Marchetti G(2013)Immune activation while on potent antiretroviral therapy can predict subsequent CD4+ T-Cell increases through 15 years of treatment HIV Clin Trials 14 61-744

[6] Kaufmann GR(2003)NK cells respond to pulmonary infection with Mycobacterium tuberculosis, but play a minimal role in protection J Immunol 171 6039-510

[7] Furrer H(2006)[NK cells and innate immunity to malaria] Med Sci (Paris) 22 739-3370

[8] Ledergerber B(2008)Functions of natural killer cells Nat Immunol 9 503-843

[9] Perrin L(2007)Natural killer cells in perinatally HIV-1-infected children exhibit less degranulation compared to HIV-1-exposed uninfected children and their expression of KIR2DL3, NKG2C, and NKp46 correlates with disease severity J Immunol 179 3362-15016

[10] Opravil M(2005)NK cells in HIV infection: paradigm for protection or targets for ambush Nat Rev Immunol 5 835-318